financetom
Business
financetom
/
Business
/
J.M. Smucker Faces 'Cautiously Optimistic' Sentiment Ahead of Fiscal Q2 Earnings, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
J.M. Smucker Faces 'Cautiously Optimistic' Sentiment Ahead of Fiscal Q2 Earnings, UBS Says
Nov 24, 2025 12:40 PM

03:01 PM EST, 11/24/2025 (MT Newswires) -- J.M. Smucker (SJM) is facing a "cautiously optimistic" sentiment ahead of its fiscal Q2 earnings on Tuesday, with investors prepared for the quarter's upside and guidance to be less robust than what was expected several weeks ago, UBS said.

The brokerage said in a Friday note that its fiscal Q2 earnings per share estimate remains unchanged at $2.07, compared with Visible Alpha consensus of $2.10.

UBS further forecasted Q2 organic sales growth of 4%, which compares with Visible Alpha consensus 4.5% and sits at the low end of the company's guidance of mid-single digit growth.

Regarding the company's fiscal 2026 guidance, UBS said that the base case expectation is that J.M. Smucker's outlook will be conservative and that the company is expected to maintain its EPS guidance with the "potential for some narrowing towards the mid to-high end."

UBS expected the company to maintain its net sales and organic sales forecast for the year at 3% to 5% and 4.5% to 6.5%, respectively, and estimated organic sales forecast of 5.7% on its end.

The firm rated J.M. Smucker as buy and lowered its price target to $120 from $121.

Price: 103.93, Change: -1.61, Percent Change: -1.53

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Nov 17, 2025
02:58 PM EST, 11/17/2025 (MT Newswires) -- Jones Lang LaSalle ( JLL ) is set to benefit from improving industry tailwinds amid attractive valuation after its Q3 results, UBS Securities said in a Sunday note. The report pointed to an outlook downgrade for its Real Estate Management Services segment for the next several quarters while Q3 margin expansion disappointed, similar...
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Nov 17, 2025
02:46 PM EST, 11/17/2025 (MT Newswires) -- Target ( TGT ) is likely to post soft Q3 on Wednesday with comparable sales down about 2% and could narrow its fiscal 2025 earnings per share guidance toward the low end of its $7 to $9 range, Oppenheimer said Monday in a pre-results report. Oppenheimer said it added conservatism to its Q4...
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025
03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast. The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings....
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Nov 17, 2025
Jazz Pharmaceuticals Plc ( JAZZ ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). What Happened: When compared to the control group that received trastuzumab...
Copyright 2023-2025 - www.financetom.com All Rights Reserved